1. Home
  2. ACB vs CCCC Comparison

ACB vs CCCC Comparison

Compare ACB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$3.20

Market Cap

188.3M

Sector

Health Care

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
CCCC
Founded
2013
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.3M
185.1M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
ACB
CCCC
Price
$3.20
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
515.7K
2.6M
Earning Date
02-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
$6.89
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$3.21
$1.09
52 Week High
$6.67
$3.82

Technical Indicators

Market Signals
Indicator
ACB
CCCC
Relative Strength Index (RSI) 36.14 44.03
Support Level N/A $2.31
Resistance Level $3.91 $2.52
Average True Range (ATR) 0.11 0.20
MACD -0.01 -0.07
Stochastic Oscillator 1.52 0.00

Price Performance

Historical Comparison
ACB
CCCC

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: